In Vitro Diagnostics Market Size, Share And Growth Trend Analysis Report By Region And Segmentation Forecasts (2026 - 2035)

In Vitro Diagnostics Market Size

The global in vitro diagnostics market, valued at USD 113 billion in 2025, is projected to reach USD 118 billion in 2026 and USD 190 billion by 2035, with a 5.4% CAGR during the forecast period 2026 to 2035.

In Vitro Diagnostics Market Report: Key Takeaways

Market Size & Trends

• In terms of test type, the laboratory segment holds the highest share (~85%) of the market.
• With regards to type of offering, the reagents segment dominates the global market with 75% of the market share.
• Based on the type of technology, the immunoassay segment holds the largest market share (nearly 35%) in 2026.
• With respect to therapeutic area, infectious diseases segment captures the highest share (~40%) in 2026.
• With regards to end users, the hospitals segment dominates the market with close to 50% of the market share.
• In terms of geographical regions, North America captures the majority of the market share, and Asia-Pacific is likely to grow at a faster pace in the near future.

In Vitro Diagnostics Market Overview

In vitro diagnostic tests (IVD) are the tests conducted on human samples, such as blood or tissue, outside the body, to allow accurate diagnosis of diseases. The term, in vitro, is derived from Latin, which translates to “within the glass”, thus referring to diagnostic tests performed outside the body. Such tests can be used to diagnose diseases, monitor the progress of treatments, and predict healthcare outcomes.

IVD products, while being non-invasive, still fall under the same regulatory requirements of medical devices due to their critical role in healthcare. Such diagnostic solutions range from self-test glucose monitoring solutions to sophisticated in-lab diagnostic procedures. In vitro diagnostic solutions cover a diverse range of tests, including blood type identification, cancer diagnostics, renal profiling, used for various applications, such as disease detection and monitoring.

According to the World Health Organization, there are over 40,000 in vitro diagnostics products available in the market. This vast array of products highlights the critical role of diagnostics in healthcare. Further, it is worth mentioning that over 70% of the healthcare decisions are made based on laboratory test results, which showcases the importance of such diagnostic tools in patient care. This can be attributed to the ability of such solutions to provide precise diagnosis and enable early intervention in order to prevent the progression of a disease.

Given the benefits offered by diagnostic assays to provide rapid diagnostic results and improve patient outcomes, the global in vitro diagnostics market is expected to grow at a healthy compounded annual growth rate (CAGR) during the forecast period. Nancy Kapila, Associate at Roots Analysis states “the IVD market growth can be attributed to several factors, including the growing demand for point of care diagnostics devices, rapid diagnostics testing, and the increasing prevalence of chronic diseases”.

In Vitro Diagnostics Market Trends

• IVD Companies are Growing Through Both Organic Expansions and Through Acquisitions: Companies active in the IVD business are expanding either through in-house capacity and facility expansion or through mergers and acquisitions. In January 2024, Roche invested $295 million for acquisition of LumiraDx’s point of care technology, highlighting the interest in POC diagnostics market segment. In February 2024, Bruker agreed to acquire ELITechGroup, a company that provides IVD instruments, for a sum of $942 million. This deal does not include the clinical chemistry business of ELITech. Spain based Werfen also acquired US based Immucor in March 2023 for a sum of $ 2 billion.
• Integration of Artificial Intelligence in IVD: As in other areas within healthcare, AI is also finding application in diagnostics market. Within IVD, AI is being employed for digital pathology and predictive diagnostics. In July 2024, European Commission published Artificial Intelligence Act (AIA) to govern the use of AI in IVDs.

In Vitro Diagnostics Market Share Insights

Market Share by Test Type

• The global IVD market is categorized into laboratory and point-of-care / POC testing.
• As per our in vitro diagnostics market report, the laboratory testing segment occupies the highest share (85%) and is expected to stay dominant during the forecast period.
• Point-of-care testing segment is expected to grow at a higher CAGR compared to laboratory testing market owing to their ability to deliver rapid test results and offer improved convenience and accessibility. IVD companies are also recognizing the demand for POC testing and investing in this market segment. We earlier talked about technology acquisition by Roche for point of care diagnostic technology.

Market Share by Type of Technology

• The global IVD market analysis highlights the distribution of this market across base technology, such as clinical chemistry, hematology, immunoassay, molecular diagnostics, and others.
• Among these types of technologies, immunoassay segment occupies the highest share (34%) in 2026 and is expected to witness substantial growth during the forecast period. This is followed by clinical chemistry segment which occupies the second largest IVD market share.

Market Share by Key Geographical Regions

• This segment highlights the distribution of in vitro diagnostics industry across various geographies, such as North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world.
• According to our projections, North America is likely to capture the majority (39%) of the market share in 2026, and this trend is unlikely to change in the future.
• The Asia Pacific in vitro diagnostics market is expected to grow at the highest CAGR among other regions (5.5%), during the forecast period 2026-2035.

Key Market Insights

Market Drivers: Growth to be Driven by Several Factors, Both Epidemiological and Technological

Increasing Prevalence of Infectious Diseases

The rising prevalence of chronic and infectious diseases around the globe have contributed to significant growth of the global IVD market. In a recent interview Mr. Rajesh Patel, CEO of Trivitron Healthcare also mentioned COVID-19 pandemic as a significant factor that created opportunity for IVD companies across the globe. On the same lines, recent emergency use authorization for an mpox diagnostic test by WHO, to control the spread of mpox, supports the demand for in vitro diagnostics created by infectious diseases.

In addition, growing geriatric population, shift of general population towards unhealthy dietary choices and sedentary lifestyle have contributed to the increase in the incidence of chronic and infectious diseases. Owing to the reasons stated above, the demand for diagnostic tests have been increasing since past few decades.

Growing Shift Towards Personalized Medicine

The aim of personalized healthcare is to customize medical treatments based on individual patient characteristics, in order to enhance treatment efficacy. Such diagnostic tests play a crucial role by offering genetic and molecular insights to enable tailored treatment approaches. By employing IVD technologies, such as molecular diagnosis and clinical chemistry, healthcare providers can predict treatment responses and optimize outcomes, in order to help patients receive personalized and optimized treatment.

Regional Analysis: North America to Hold Majority Share; Middle East and North Africa is Expected to be the Fastest Growing Market

Presently, North America in vitro diagnostics market captures 39% of the market share. However, it is worth highlighting that, owing to the rising demand for in vitro diagnostics and increased investments in the region, market in Asia is likely to grow at a higher CAGR (5.5%) as compared to other regions in the coming years. The US is expected to occupy the majority of the market share in North America, driven by factors such as the growing prevalence of early disease diagnosis, increasing incidences of infectious and chronic diseases, and the adoption of point-of-care testing devices for accurate and timely results.

Additionally, Europe is expected to become the second most dominant region in terms of market share owing to various factors such as rising healthcare expenditure, well-established infrastructure, and a large pool of patients suffering from infectious diseases and cancer. Furthermore, in Asia, developing countries such as India and China are expected to witness the highest growth rate.

The IVD market growth over the next decade is likely to be the result of rising prevalence of chronic diseases, a rapidly growing aging population and increasing healthcare expenditure.

Key Companies in In Vitro Diagnostics Market

Examples of in vitro diagnostics companies (also profiled in this report, the complete list of companies is available in the full report) include Abbott Laboratories, Agilent, Becton Dickinson, bioMérieux, Bio-Rad, Danaher Corporation, DiaSorin, Exact Sciences, Fujifilm, Gold Standard Diagnostics, Grifols, Hologic, Illumina, LabCorp, Qiagen, Quest Diagnostics, QuidelOrtho, Roche, Siemens Healthineers, Sysmex, Thermo Fisher Scientific and Werfen. This global IVD market report includes an easily searchable excel database of the leading companies that offer in vitro diagnostic solutions.

In Vitro Diagnostics Market Segmentation Insights

Frequently Asked Questions